Abstract
With increasing approvals of viral vector-based gene therapies, the industry is shifting its focus to the expansion of viral vector manufacturing to meet the demands of the growing number of therapies on the market. Continuous improvements in the efficiency of viral vector production, as well as optimization of complex bioproduction processes, are essential to meet demand and get lifesaving therapies to patients quickly. This must be carefully balanced with consistency and quality of the final product. In this article, multiple applications and technologies to address current manufacturing challenges and solutions to increase overall viral vector yield throughout development will be explored. Case studies will be presented to demonstrate the progress associated with process intensification and optimization from benchtop development to large-scale commercial manufacturing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
